Whitehawk Therapeutics Advances ADC Pipeline with Phase 1 Trials, $145.7M Cash Runway
Event summary
- Whitehawk Therapeutics reported $145.7M in cash, cash equivalents, and short-term investments as of December 31, 2025, up from $47.2M a year earlier.
- The company is actively recruiting Phase 1 trials for PTK7-targeted HWK-007 and MUC16-targeted HWK-016 ADCs.
- HWK-206 is on track for IND submission in mid-2026 and Phase 1 start in Q3 2026.
- Whitehawk presented data at the AACR-NCI-EORTC meeting confirming PTK7 as a broadly expressed tumor marker in ~70% of tumors.
The big picture
Whitehawk Therapeutics is advancing its ADC pipeline with two active Phase 1 trials and a third IND submission planned for mid-2026. The company's cash position of $145.7M provides a runway into 2028, but the success of its clinical programs will be critical in sustaining investor confidence. The presentation of PTK7 as a broadly expressed tumor marker underscores the strategic focus on underexploited tumor targets.
What we're watching
- Clinical Progress
- Whether the Phase 1 trials for HWK-007 and HWK-016 will deliver initial results in 1H 2027 as planned.
- Financial Sustainability
- The pace at which Whitehawk will burn through its $145.7M cash position and whether it will need additional financing before 2028.
- Regulatory Strategy
- How the new CMO, Margaret Dugan, will influence the company's early-stage clinical development and regulatory strategy.
Related topics